Tim-3 as a diagnostic and prognostic biomarker of osteosarcoma
Open accessThe DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Abstract
Osteosarcoma is the most frequent primary bone tumor that affects adolescents and children. However, diagnostic and prognostic biomarkers for osteosarcoma remain lacking. (Tim-3) T-cell immunoglobulin domain and mucin domain-3, which negatively regulates T cell helper (Th1) cells and affects cytokine expression, has attracted increasing attention due to its critical role in regulating both adaptive and innate immune cells. In this study, we evaluated serum soluble Tim-3 level in osteosarcoma patients to explore its diagnostic and prognostic value for this particular malignancy. Serum soluble Tim-3 level was measured with enzyme-linked immunosorbent assay in 120 osteosarcoma patients, 120 benign bone tumors patients and 120 healthy controls, followed by analysis of the correlation with clinic pathological characteristics. Receiver operating curves, Kaplan-Meier curves, and log-rank analyses as well as Cox proportional hazard models were used to evaluate the diagnostic and prognostic significance. Serum solubleTim-3 level was remarkably elevated in osteosarcoma patients. Osteosarcoma patients with larger tumor size, late stages and distant metastases were accompanied with higher levels of Tim-3. ROC/AUC analysis indicated thatTim-3 served as a reliable marker to distinguish healthy participants from Tim-3 patients. Osteosarcoma patients with higher Tim-3 had relatively lower survival. Multivariate analyses for overall survival revealed that high serum soluble Tim-3 level was an independent prognostic factor for osteosarcoma. Furthermore, Tim-3 levels of CD8+ and CD4+ T cells were elevated in peripheral circulation of osteosarcoma patients. Therefore, It was indicated in our research that elevated serum soluble Tim-3 level might be a novel potential diagnostic and prognostic biomarker for osteosarcoma patients.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“TIM-3 and Gal-9 are expressed in osteosarcoma tissues, and the interaction of TIM-3 and Gal-9 promotes the apoptosis of CD4+ and CD8+ T cells in the TME of osteosarcoma, which is related with poor prognosis in osteosarcoma patients [99].”
From Advances on immunotherapy for osteosarcoma (2024) · cites this paper as [99]
Citations
Cites
Translational biology of osteosarcoma
Kansara, M., Teng, M. W., Smyth, M. J., & Thomas, D. M. (2014) · Nature Reviews Cancer · doi:10.1038/nrc3838 · Cited by 1,294
CEACAM1 regulates TIM-3-mediated tolerance and exhaustion
Huang, Y.-H., Zhu, C., Kondo, Y., Anderson, A. C., Gandhi, A., Russell, A., Dougan, S. K., Petersen, B.-S., Melum, E., Pertel, T., et al. (2015) · Nature · doi:10.1038/nature13848 · Cited by 717
Lindsey, B. A., Markel, J. E., & Kleinerman, E. S. (2017) · Rheumatology and Therapy · doi:10.1007/s40744-016-0050-2 · Cited by 487
Reversal of NK-Cell Exhaustion in Advanced Melanoma by Tim-3 Blockade
da Silva, I. P., Gallois, A., Jimenez-Baranda, S., Khan, S., Anderson, A. C., Kuchroo, V. K., Osman, I., & Bhardwaj, N. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-13-0171 · Cited by 424
Tim-3: An Emerging Target in the Cancer Immunotherapy Landscape
Anderson, A. C. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0039 · Cited by 305
New targets and approaches in osteosarcoma
Gill, J., Ahluwalia, M. K., Geller, D., & Gorlick, R. (2013) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2012.09.003 · Cited by 273
New molecular insights into osteosarcoma targeted therapy
Yang, J., & Zhang, W. (2013) · Current Opinion in Oncology · doi:10.1097/cco.0b013e3283622c1b · Cited by 262
Molecular genetics of osteosarcoma
Rickel, K., Fang, F., & Tao, J. (2017) · Bone · doi:10.1016/j.bone.2016.10.017 · Cited by 244
Fourcade, J., Sun, Z., Pagliano, O., Chauvin, J.-M., Sander, C., Janjic, B., Tarhini, A. A., Tawbi, H. A., Kirkwood, J. M., Moschos, S., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-2908 · Cited by 209
Natural compounds targeting major cell signaling pathways: a novel paradigm for osteosarcoma therapy
Angulo, P., Kaushik, G., Subramaniam, D., Dandawate, P., Neville, K., Chastain, K., & Anant, S. (2017) · Journal of Hematology & Oncology · doi:10.1186/s13045-016-0373-z · Cited by 184
Research works printed but not linked: 3
- Zhu LB, 2014, Int J Clin Exp Pathol, 7, 3984
- Shen P, 2016, Am J Transl Res, 8, 3419
- Cheng G, 2015, Int J Clin Exp Pathol, 8, 9452
Cited by
TIM3 comes of age as an inhibitory receptor
Wolf, Y., Anderson, A. C., & Kuchroo, V. K. (2020) · Nature Reviews Immunology · doi:10.1038/s41577-019-0224-6 · Cited by 959
Advances on immunotherapy for osteosarcoma
Yu, S., & Yao, X. (2024) · Molecular Cancer · doi:10.1186/s12943-024-02105-9 · Cited by 270
Ligon, J. A., Choi, W., Cojocaru, G., Fu, W., Hsiue, E. H.-C., Oke, T. F., Siegel, N., Fong, M. H., Ladle, B., Pratilas, C. A., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001772 · Cited by 124
Immune checkpoints in osteosarcoma: Recent advances and therapeutic potential
Yang, W., Tang, F., Tu, C., Hornicek, F. J., Duan, Z., & Min, L. (2022) · Cancer Letters · doi:10.1016/j.canlet.2022.215887 · Cited by 114
Gao, J., Qiu, X., Li, X., Fan, H., Zhang, F., Lv, T., & Song, Y. (2018) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2018.02.114 · Cited by 106
Metadata
- Authors
- Ge, W., Li, J., Fan, W., Xu, D., & Sun, S.
- Affiliations
- People’s Hospital of Rizhao (CN)
- Department of Orthopedics & Traumatology, Rizhao Hospital of Traditional Chinese Medicine, Rizhao, China
- Corresponding author
- Sun, Shangfei
- Venue
- Tumor Biology
- Publisher
- SAGE Publications
- Published
- 2017-07
- Volume
- 39
- Issue
- 7
- Pages
- 101042831771564
- ISSN
- 1010-4283 (ISSN-L)
- 1423-0380
- OpenAlex
- W2735051780
- Cited by
- 45
- References
- 30
- Citations by year
- 2026: 3 · 2024: 6 · 2023: 4 · 2022: 9 · 2021: 10 · 2020: 8 · 2019: 2 · 2018: 2 · 2017: 1
- FWCI
- 2.94
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by-nc
- journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)
- Locations
- Tumor Biology (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Health Sciences › Medicine › Oncology › Sarcoma Diagnosis and Treatment
- Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone Tumor Diagnosis and Treatments
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Keywords
- TIM-3, osteosarcoma, soluble TIM-3, serum biomarkers, diagnostic biomarkers, prognostic factors, overall survival, CD8+ T cells, CD4+ T cells, T cell regulation, bone tumors
- MeSH terms
- Hepatitis A Virus Cellular Receptor 2, Adolescent, Adult, Female, Humans, Male, Prognosis, Osteosarcoma, Biomarkers, Tumor, Gene Expression Regulation, Neoplastic, Disease-Free Survival
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Tim-3 as a diagnostic and prognostic biomarker of osteosarcoma. https://app.cochat.ai/papers/10.1177/1010428317715643
- The paper
- Ge, W., Li, J., Fan, W., Xu, D., & Sun, S. (2017). Tim-3 as a diagnostic and prognostic biomarker of osteosarcoma. Tumor Biology. https://doi.org/10.1177/1010428317715643
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.